Stockscreener 앱 받기
34.00
1.65%
-0.56
시간 외 거래:
33.80
-0.20
-0.59%
전일 마감가:
$34.56
열려 있는:
$34
하루 거래량:
1.96M
Relative Volume:
0.81
시가총액:
$4.25B
수익:
$1.12B
순이익/손실:
$5.00M
주가수익비율:
3,400.00
EPS:
0.01
순현금흐름:
$-383.00M
1주 성능:
-6.08%
1개월 성능:
-4.42%
6개월 성능:
+119.72%
1년 성능:
+195.31%
1일 변동 폭
$33.64
$34.37
1주일 범위
$33.64
$37.66
52주 변동 폭
$7.62
$38.00
Indivior Plc Stock (INDV) Company Profile
명칭
Indivior Plc
전화
804-379-1090
주소
234 BATH ROAD, SLOUGH, BERKSHIRE
INDV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INDV
Indivior Plc
|
34.00 | 4.32B | 1.12B | 5.00M | -383.00M | 0.01 |
|
ZTS
Zoetis Inc
|
124.64 | 55.23B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.00 | 51.37B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.48 | 37.62B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
476.86 | 20.77B | 3.08B | 1.24B | 1.07B | 25.61 |
Indivior Plc Stock (INDV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-06 | 개시 | H.C. Wainwright | Buy |
| 2025-07-22 | 재개 | Jefferies | Buy |
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2024-07-23 | 개시 | Piper Sandler | Overweight |
| 2024-04-03 | 개시 | Craig Hallum | Buy |
| 2023-07-13 | 개시 | Northland Capital | Outperform |
모두보기
Indivior Plc 주식(INDV)의 최신 뉴스
Aug Setups: Does Indivior PLC stock trade at a discount to peersMarket Activity Summary & Safe Capital Growth Tips - moha.gov.vn
Risks Report: Will Indivior PLC stock remain a Wall Street favorite2025 Technical Patterns & Free Real-Time Volume Trigger Notifications - moha.gov.vn
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes - Finviz
Volume Recap: Is Indivior PLC forming higher highs and higher lows2025 Market Sentiment & Verified Entry Point Signals - baoquankhu1.vn
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug - Finviz
Take the Zacks Approach to Beat the Markets: Indivior, FIGS & Ulta Beauty in Focus - Yahoo Finance
Indivior stock price target raised to $48 from $35 at H.C. Wainwright - Investing.com Nigeria
INDV: Analyst Raises Price Target to $48.00, Maintains Buy Ratin - GuruFocus
Naloxone Market Is Going to Boom |EMERGENT, Indivior PLC, Akorn, Inc - openPR.com
Indivior PLC (INDV) Announces Full-Year 2026 Financial Guidance - Finviz
Indivior (NasdaqGS:INDV) Valuation Check After Strong Long Term Returns And Recent Price Consolidation - Yahoo Finance UK
Indivior PLCOrdinary Shares (NQ: INDV - FinancialContent
Craig-Hallum raises Indivior stock price target to $50 on strong 2026 outlook - Investing.com Nigeria
Aug Closing: Why hedge funds are buying Indivior PLC stockWall Street Watch & Safe Entry Trade Signal Reports - moha.gov.vn
Can Indivior PLC stock double in next 5 years2025 Volume Leaders & Safe Entry Point Alerts - ulpravda.ru
Why Indivior PLC (2IVB) stock is a strong analyst pickWeekly Risk Summary & Safe Entry Point Identification - ulpravda.ru
Why retail investors pile into Indivior PLC stockJuly 2025 Momentum & Fast Moving Market Watchlists - ulpravda.ru
Is Indivior PLC stock a top pick in earnings season2025 Macro Impact & Fast Exit Strategy with Risk Control - ulpravda.ru
What margin trends mean for Indivior PLC stockWeekly Trade Report & Real-Time Chart Pattern Alerts - ulpravda.ru
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug - Finviz
Published on: 2026-01-08 20:56:58 - ulpravda.ru
How Indivior PLC stock performs during Fed tightening cycles2025 Key Lessons & Stepwise Entry/Exit Trade Alerts - ulpravda.ru
What analyst consensus says on Indivior PLC stock2025 AllTime Highs & Daily Technical Stock Forecast Reports - ulpravda.ru
Indivior Issues FY 2026 Financial Guidance - Nasdaq
Indivior shares rise after FY26 guidance tops consensus expectations By Investing.com - Investing.com Nigeria
Indivior PLC Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Indivior Expects Up to $1.20 Billion in 2026 Net Revenue - MarketScreener
(INDV) Indivior Expects 2026 Revenue Range $1.13B$1.2B, vs. FactSet Est of $1.19B - MarketScreener
Indivior forecasts 11% SUBLOCADE growth, 35% EBITDA increase for 2026 By Investing.com - Investing.com South Africa
Indivior PLC Announces Full-Year 2026 Financial Guidance and Business Highlights - Quiver Quantitative
Indivior : Financial Document - MarketScreener
Indivior PLC Provides 2026 Financial Guidance and Business Update - TradingView — Track All Markets
Indivior Provides Full-Year 2026 Financial Guidance and Business Update - Bluefield Daily Telegraph
Opioid treatment maker Indivior maps 2026 growth and U.S. move - Stock Titan
Indivior price target raised to $40 from $30 at Northland - MSN
Indivior director Stejbach buys $27,429 in shares By Investing.com - Investing.com Australia
Insider Buying: Barbara Ryan Acquires Shares of Indivior PLC - GuruFocus
Ryan Barbara, Indivior director, buys $27,429 in shares By Investing.com - Investing.com Australia
Wheadon David E., Indivior director, buys $62,680 in shares By Investing.com - Investing.com South Africa
Indivior director Ninivaggi buys $27,429 in shares By Investing.com - Investing.com Nigeria
Humphreys Keith buys Indivior (INDV) shares worth $27,429 By Investing.com - Investing.com Canada
Humphreys Keith buys Indivior (INDV) shares worth $27,429 - Investing.com
Indivior director Stejbach buys $27,429 in shares - Investing.com
Ryan Barbara, Indivior director, buys $27,429 in shares - Investing.com
Indivior shareholders approve scheme of arrangement - MSN
Will Indivior PLC stock reach all time highs in 20252026 world cup usa national team quarterfinals defensive leaders low block defense match prediction insights - ulpravda.ru
New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations - Eastern Progress
This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table - AOL.com
Indivior outlines $1.03B–$1.08B 2025 revenue guidance and cost structure overhaul through action agenda - MSN
Suboxone Market is Going to Booming Growth 2025 With Top Key - openPR.com
Indivior PLC stock: volatile swings, legal overhangs and a nervous market mood - AD HOC NEWS
Indivior Plc (INDV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
2.43%
자본화:
|
볼륨(24시간):